Abstract
1347 injections of HbOC have been given to 784 children of 2-24 mos. Associated symptoms post-vaccination included T≥38°C - 6%; local redness/warmth- 3%, swelling-2% and were not affected by the child's age, ab liter or dose sequence. Ab assays include 3H-HbPs RIA, anti-HbPs ab isotype, bactericidal (BC) activity. GMT of anti-HbPs ab titers, μg/ml (No. sera analyzed), after 25 μg dose(s) include:
Vaccination of children at 15-22 mos. substantially increased anti-HbPs IgG and BC activities; similar studies are being completed for vaccinated infants. It can be concluded that HbOC is a safe, effective vaccine against Hib disease for all aged children.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Smith, D., Johnson, C., Biologics, P. et al. HAEMOPHILUS B OLIGOSACCHARIDE-CRM (HbOC) VACCINE: CONTINUING CLINICAL STUDIES. Pediatr Res 21 (Suppl 4), 334 (1987). https://doi.org/10.1203/00006450-198704010-01004
Issue Date:
DOI: https://doi.org/10.1203/00006450-198704010-01004